Abstract
Incidence of second malignancies in patients with advanced lung cancer is not well-studied, in part because of a short survival in this patient population. Apart from a genetic predisposition, various environmental hazards may also be at play in their pathogenesis. Chronic smoking exposure decreases T-cell responsiveness and stimulates production of a variety of inhibitory cytokines. Paclitaxel has been associated with several immunosuppressive effects such as decreased numbers and activity of dendritic cells, NK-cells, and monocytes. We herein describe the first series of lung cancer patients who developed colonic polyps/colon cancer either during or immediately following chemotherapy with paclitaxel, suggesting a possible role of this agent in their pathogenesis.
MeSH terms
-
Aged, 80 and over
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Colonic Neoplasms / chemically induced
-
Colonic Neoplasms / immunology*
-
Colonic Neoplasms / pathology
-
Colonic Polyps / chemically induced
-
Colonic Polyps / immunology*
-
Colonic Polyps / physiopathology
-
Female
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / immunology
-
Male
-
Middle Aged
-
Neoplasms, Second Primary / chemically induced
-
Neoplasms, Second Primary / drug therapy
-
Neoplasms, Second Primary / immunology*
-
Neoplasms, Second Primary / pathology
-
Paclitaxel / adverse effects*
-
Paclitaxel / therapeutic use
-
Precancerous Conditions / chemically induced
-
Precancerous Conditions / immunology*
-
Precancerous Conditions / pathology
Substances
-
Antineoplastic Agents, Phytogenic
-
Immunosuppressive Agents
-
Paclitaxel